First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.
News|Articles|February 13, 2019
Talzenna for gBRCAm HER2-negative Locally Advanced or Metastatic Breast Cancer
Author(s)Drew Boxler
Advertisement
Talzenna (talazoparib, Pfizer)
Indications: Adult Patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.
Dosage: 1 mg singly oral daily dose until disease progression or unacceptable toxicity occurs
Contraindications: None
Advertisement
Related to this article
The once daily tablet is expected to reach US patients in October 2026.
The label expansion adds patients 12 years of age and older to the once daily alopecia areata indication.
This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.
The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.
What pharmacy technicians say would actually make them feel seen on World Pharmacy Technician Day, and the other 364 days of the year.
The analysis is not a head-to-head trial, and the weight loss gap reached statistical significance under 1 of 2 estimands.
Advertisement
Advertisement
Trending on Drug Topics
1
Technicians Aren't Asking for a Party
2
Indirect Comparison Links Tirzepatide to Greater Weight Loss Than Semaglutide
3
Infections Fall With Azithromycin for Unscheduled Cesarean Deliveries
4
Study Links Oral Menopausal Hormone Therapy to Thrombotic Risk
5